Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
VIVO's Cash to Debt is ranked higher than
83% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. VIVO: No Debt )
VIVO' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt

Equity to Asset 0.91
VIVO's Equity to Asset is ranked higher than
96% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. VIVO: 0.91 )
VIVO' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.92
Current: 0.91

0.35
0.92
Interest Coverage No Debt
VIVO's Interest Coverage is ranked higher than
80% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. VIVO: No Debt )
VIVO' s 10-Year Interest Coverage Range
Min: 4.78   Max: 9999.99
Current: No Debt

4.78
9999.99
F-Score: 4
Z-Score: 30.37
M-Score: -2.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.10
VIVO's Operating margin (%) is ranked higher than
96% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. VIVO: 28.10 )
VIVO' s 10-Year Operating margin (%) Range
Min: -22.13   Max: 32.9
Current: 28.1

-22.13
32.9
Net-margin (%) 18.69
VIVO's Net-margin (%) is ranked higher than
96% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. VIVO: 18.69 )
VIVO' s 10-Year Net-margin (%) Range
Min: -18.18   Max: 22.09
Current: 18.69

-18.18
22.09
ROE (%) 22.07
VIVO's ROE (%) is ranked higher than
96% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. VIVO: 22.07 )
VIVO' s 10-Year ROE (%) Range
Min: -44.78   Max: 27.89
Current: 22.07

-44.78
27.89
ROA (%) 19.98
VIVO's ROA (%) is ranked higher than
97% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.30 vs. VIVO: 19.98 )
VIVO' s 10-Year ROA (%) Range
Min: -15.57   Max: 21.52
Current: 19.98

-15.57
21.52
ROC (Joel Greenblatt) (%) 63.52
VIVO's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.19 vs. VIVO: 63.52 )
VIVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34.55   Max: 82.47
Current: 63.52

-34.55
82.47
Revenue Growth (%) 8.90
VIVO's Revenue Growth (%) is ranked higher than
78% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. VIVO: 8.90 )
VIVO' s 10-Year Revenue Growth (%) Range
Min: 2.8   Max: 22.6
Current: 8.9

2.8
22.6
EBITDA Growth (%) 10.60
VIVO's EBITDA Growth (%) is ranked higher than
81% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. VIVO: 10.60 )
VIVO' s 10-Year EBITDA Growth (%) Range
Min: -2.3   Max: 22.5
Current: 10.6

-2.3
22.5
EPS Growth (%) 11.90
VIVO's EPS Growth (%) is ranked higher than
82% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. VIVO: 11.90 )
VIVO' s 10-Year EPS Growth (%) Range
Min: -27.9   Max: 35.7
Current: 11.9

-27.9
35.7
» VIVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

VIVO Guru Trades in Q3 2013

Chuck Royce 19,600 sh (+276.92%)
Joel Greenblatt 155,306 sh (+85.08%)
Jim Simons 140,976 sh (+42.83%)
Paul Tudor Jones 12,600 sh (+28.57%)
John Keeley 87,470 sh (+11.9%)
Mario Gabelli 90,000 sh (unchged)
John Hussman 12,500 sh (unchged)
» More
Q4 2013

VIVO Guru Trades in Q4 2013

Jim Simons 237,495 sh (+68.46%)
John Keeley 92,870 sh (+6.17%)
Mario Gabelli 90,000 sh (unchged)
Chuck Royce 18,200 sh (-7.14%)
John Hussman 10,000 sh (-20%)
Joel Greenblatt 114,807 sh (-26.08%)
Paul Tudor Jones 7,600 sh (-39.68%)
» More
Q1 2014

VIVO Guru Trades in Q1 2014

Paul Tudor Jones 28,090 sh (+269.61%)
Jim Simons 531,076 sh (+123.62%)
John Hussman 15,000 sh (+50%)
John Keeley 107,610 sh (+15.87%)
Mario Gabelli 92,000 sh (+2.22%)
Chuck Royce 18,200 sh (unchged)
Joel Greenblatt 61,960 sh (-46.03%)
» More
Q2 2014

VIVO Guru Trades in Q2 2014

Mario Gabelli 130,000 sh (+41.3%)
Jim Simons 695,276 sh (+30.92%)
Joel Greenblatt 61,641 sh (-0.51%)
John Keeley 102,510 sh (-4.74%)
Chuck Royce 16,100 sh (-11.54%)
John Hussman 7,500 sh (-50%)
Paul Tudor Jones 10,887 sh (-61.24%)
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Reduce -50%0.01%$19.34 - $22.37 $ 18.58-10%7500
Mario Gabelli 2014-06-30 Add 41.3%$19.34 - $22.37 $ 18.58-10%130000
Joel Greenblatt 2014-03-31 Reduce -46.03%0.03%$20.43 - $27.24 $ 18.58-19%61960
John Hussman 2014-03-31 Add 50%0.01%$20.43 - $27.24 $ 18.58-20%15000
Joel Greenblatt 2013-12-31 Reduce -26.08%0.03%$22.75 - $26.6 $ 18.58-24%114807
Joel Greenblatt 2013-09-30 Add 85.08%0.06%$21.93 - $24.86 $ 18.58-20%155306
Joel Greenblatt 2013-06-30 Add 31.32%0.02%$19.52 - $22.6 $ 18.58-14%83913
John Keeley 2013-06-30 Add 43.51%0.01%$19.52 - $22.6 $ 18.58-14%78170
John Hussman 2013-06-30 Add 78.57%0.01%$19.52 - $22.6 $ 18.58-14%12500
John Keeley 2013-03-31 Add 27.95%0.01%$20.25 - $22.815 $ 18.58-14%54470
John Hussman 2013-03-31 New Buy0.01%$20.25 - $22.815 $ 18.58-14%7000
Mario Gabelli 2012-12-31 Add 23.08%$18.75 - $20.6 $ 18.58-6%80000
Joel Greenblatt 2012-09-30 Add 237%0.05%$16.3 - $20.61 $ 18.581%55811
John Keeley 2012-09-30 Add 36.96%$16.3 - $20.61 $ 18.581%41470
Mario Gabelli 2012-09-30 Add 62.5%$16.3 - $20.61 $ 18.581%65000
Joel Greenblatt 2012-06-30 New Buy0.03%$18.27 - $20.83 $ 18.58-4%16561
John Keeley 2012-03-31 Add 31.88%$17.29 - $20.12 $ 18.588%27880
Mario Gabelli 2012-03-31 New Buy$17.29 - $20.12 $ 18.588%35000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.80
VIVO's P/E(ttm) is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 21.80 )
VIVO' s 10-Year P/E(ttm) Range
Min: 18.94   Max: 48.85
Current: 21.8

18.94
48.85
P/B 4.80
VIVO's P/B is ranked higher than
67% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.39 vs. VIVO: 4.80 )
VIVO' s 10-Year P/B Range
Min: 4.68   Max: 11.7
Current: 4.8

4.68
11.7
P/S 4.10
VIVO's P/S is ranked higher than
68% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. VIVO: 4.10 )
VIVO' s 10-Year P/S Range
Min: 2.06   Max: 10.95
Current: 4.1

2.06
10.95
PFCF 26.80
VIVO's PFCF is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 26.80 )
VIVO' s 10-Year PFCF Range
Min: 14.34   Max: 69.92
Current: 26.8

14.34
69.92
EV-to-EBIT 13.67
VIVO's EV-to-EBIT is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 13.67 )
VIVO' s 10-Year EV-to-EBIT Range
Min: 12.5   Max: 37.1
Current: 13.67

12.5
37.1
PEG 4.47
VIVO's PEG is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 4.47 )
VIVO' s 10-Year PEG Range
Min: 0.98   Max: 37
Current: 4.47

0.98
37
Shiller P/E 22.60
VIVO's Shiller P/E is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 22.60 )
VIVO' s 10-Year Shiller P/E Range
Min: 22.17   Max: 105.81
Current: 22.6

22.17
105.81
Current Ratio 6.70
VIVO's Current Ratio is ranked higher than
89% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. VIVO: 6.70 )
VIVO' s 10-Year Current Ratio Range
Min: 1.85   Max: 10.21
Current: 6.7

1.85
10.21
Quick Ratio 4.48
VIVO's Quick Ratio is ranked higher than
85% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. VIVO: 4.48 )
VIVO' s 10-Year Quick Ratio Range
Min: 1.06   Max: 8.77
Current: 4.48

1.06
8.77

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.30
VIVO's Dividend Yield is ranked higher than
90% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.22 vs. VIVO: 4.30 )
VIVO' s 10-Year Dividend Yield Range
Min: 1.24   Max: 4.83
Current: 4.3

1.24
4.83
Dividend Payout 0.92
VIVO's Dividend Payout is ranked higher than
83% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 0.92 )
VIVO' s 10-Year Dividend Payout Range
Min: 0.27   Max: 5.8
Current: 0.92

0.27
5.8
Dividend growth (3y) 0.90
VIVO's Dividend growth (3y) is ranked higher than
65% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. VIVO: 0.90 )
VIVO' s 10-Year Dividend growth (3y) Range
Min: 0.9   Max: 37.5
Current: 0.9

0.9
37.5
Yield on cost (5-Year) 4.99
VIVO's Yield on cost (5-Year) is ranked higher than
84% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.53 vs. VIVO: 4.99 )
VIVO' s 10-Year Yield on cost (5-Year) Range
Min: 1.47   Max: 5.74
Current: 4.99

1.47
5.74
Share Buyback Rate -0.60
VIVO's Share Buyback Rate is ranked higher than
84% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. VIVO: -0.60 )
VIVO' s 10-Year Share Buyback Rate Range
Min: 0.3   Max: -6.1
Current: -0.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 34.40
VIVO's Price/Net Cash is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 34.40 )
VIVO' s 10-Year Price/Net Cash Range
Min: 14.91   Max: 172.21
Current: 34.4

14.91
172.21
Price/Net Current Asset Value 12.73
VIVO's Price/Net Current Asset Value is ranked higher than
83% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 12.73 )
VIVO' s 10-Year Price/Net Current Asset Value Range
Min: 9.39   Max: 97.23
Current: 12.73

9.39
97.23
Price/Tangible Book 5.95
VIVO's Price/Tangible Book is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.63 vs. VIVO: 5.95 )
VIVO' s 10-Year Price/Tangible Book Range
Min: 3.58   Max: 17.7
Current: 5.95

3.58
17.7
Price/DCF (Projected) 1.82
VIVO's Price/DCF (Projected) is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 1.82 )
VIVO' s 10-Year Price/DCF (Projected) Range
Min: 1.01   Max: 4.18
Current: 1.82

1.01
4.18
Price/Median PS Value 0.77
VIVO's Price/Median PS Value is ranked higher than
90% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.39 vs. VIVO: 0.77 )
VIVO' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 1.95
Current: 0.77

0.12
1.95
Price/Peter Lynch Fair Value 3.97
VIVO's Price/Peter Lynch Fair Value is ranked higher than
90% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 3.97 )
VIVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.89   Max: 7.49
Current: 3.97

0.89
7.49
Price/Graham Number 2.39
VIVO's Price/Graham Number is ranked higher than
83% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. VIVO: 2.39 )
VIVO' s 10-Year Price/Graham Number Range
Min: 1.99   Max: 5.67
Current: 2.39

1.99
5.67
Earnings Yield (Greenblatt) 7.30
VIVO's Earnings Yield (Greenblatt) is ranked higher than
76% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. VIVO: 7.30 )
VIVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 8
Current: 7.3

2.7
8
Forward Rate of Return (Yacktman) 8.59
VIVO's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. VIVO: 8.59 )
VIVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 2353.3
Current: 8.59

0.8
2353.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MR4.Germany
Meridian Bioscience Inc. was incorporated in Ohio in 1976. It is a fully-integrated life science Company whose businesses in the development, manufacture, sale and distribution of diagnostic test kits, mainly for certain respiratory, gastrointestinal, viral and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company's operating segments are US Diagnostics, European Diagnostics, and Life Science. The Company's U.S. Diagnostics operating segment's business focuses on the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal, viral, respiratory and parasitic infectious diseases. Its European Diagnostics operating segment's business focuses on the sale and distribution of diagnostic test kits, manufactured both by the Company's U.S. Diagnostics operating segment and by third-party vendors. Life Science operating segment's business focuses on the development, manufacture, sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic companies, as well as contract development and manufacturing services under clinical cGMP conditions. The company's competitors are Abbott Laboratories Inc., Becton, Dickinson and Company, Thermo Fisher and Siemens, Quidel Corporation and Inverness Medical Innovations.
» More Articles for VIVO

Headlines

Articles On GuruFocus.com
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
13 Stocks Delivering What's Important: Dividend Increases Jan 27 2014 
68 Top Dividend Stocks with Ex-Dividend Date in August 2013 Jul 29 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
comment on VIVO Jan 26 2013 
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
15 of the Best Growing Dividend Achievers Jul 30 2012 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
The Best Yielding Healthcare Dividend Stocks with Fastest Earnings Growth Feb 02 2012 

More From Other Websites
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Other Events Sep 15 2014
Meridian Bioscience Offers Testing Solutions to Premier Sep 04 2014
Meridian Bioscience's Earnings Outlook Show Flat Growth Sep 03 2014
Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic... Sep 03 2014
Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal... Sep 02 2014
MERIDIAN BIOSCIENCE INC Financials Aug 19 2014
MERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Aug 11 2014
Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License... Aug 06 2014
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates Jul 28 2014
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Jul 28 2014
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash... Jul 24 2014
[video] Akers CEO: We Are Growing Globally and Now Is the Time for Investors to Take Notice Jul 10 2014
Meridian receives Canadian licenses for two illumigene platforms May 28 2014
Meridian Bioscience Receives Canadian Licenses for illumigene® Mycoplasma and illumigene®... May 28 2014
The Zacks Analyst Blog Highlights: Boeing, Embraer, Meridian Bioscience, Cardica and Eagle... May 27 2014
Meridian Bioscience Down to Strong Sell May 23 2014
MERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report May 12 2014
3 Small-Cap 'Frozen Angels' For Your Dividend Growth Portfolio May 07 2014
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK